BioAdaptives Announces National Launch of NeuroRush™ — A Cutting-Edge Adaptogenic Nootropic for Mental Clarity, Focus, and Resilience
Rhea-AI Summary
BioAdaptives (OTC:BDPTD) announced the national launch of NeuroRush™, a next-generation nootropic supplement, scheduled for commercial release in August/September 2025. The product combines six clinically studied ingredients including Rhodiola Rosea, Ashwagandha, Bacopa Monnieri, Panax Ginseng, and Mucuna Pruriens.
The supplement will be available in two formulations: one with natural caffeine and a caffeine-free version. Following successful test market results, the company plans to distribute NeuroRush™ through online retailers, direct-to-consumer channels, and health & wellness partners nationwide.
Positive
- Strong results reported in targeted test market trials
- Product offers two formulations to address different consumer needs
- Multiple distribution channels planned for nationwide reach
Negative
- None.
NeuroRush™ delivers a unique blend of adaptogens and nootropic herbs designed to enhance cognitive performance, stress response and long-term brain health, without dependency or burnout.
LAS VEGAS, July 16, 2025 (GLOBE NEWSWIRE) -- BioAdaptives, Inc. (OTC: BDPT), an innovator in evidence-based wellness solutions, today announced the upcoming national release of NeuroRush™, a next-generation nootropic designed to support sustained cognitive performance, mental clarity, and stress adaptability. Following strong results in targeted test markets, NeuroRush™ is scheduled for full commercial release in August/September 2025.
Developed as a premium adaptogen-based formula, NeuroRush™ combines six clinically studied ingredients—including Rhodiola Rosea, Ashwagandha, Bacopa Monnieri, Panax Ginseng, and Mucuna Pruriens—to deliver a balanced, non-jittery experience designed for high-functioning individuals. The product will be available in two formulations: one with natural caffeine for fast-acting mental energy, and a caffeine-free version for users sensitive to stimulants.
“We saw exceptional results in controlled launch markets,” said James Keener, CEO of BioAdaptives. “Customers reported not only better focus and productivity, but also a noticeable improvement in mood, stress control, and cognitive stamina. NeuroRush™ represents our commitment to delivering plant-based performance solutions grounded in science.”
NeuroRush™ is formulated to target multiple pathways involved in brain function and stress resilience, making it ideal for professionals, students, athletes, and older adults seeking enhanced mental performance without dependency or crash. The proprietary blend includes adaptogens, neurotransmitter precursors, and nootropic herbs that work synergistically to support dopamine balance, neuroplasticity, and mental endurance.
BioAdaptives plans to distribute NeuroRush™ through select online retailers, direct-to-consumer channels, and strategic health & wellness partners nationwide. Initial consumer feedback has highlighted NeuroRush™ as a high-performance solution that stands apart from conventional stimulant-based brain products.
About BioAdaptives, Inc.
BioAdaptives, Inc. develops and markets science-based natural health and wellness products for both humans and animals. Its formulations leverage cutting-edge research in stem cell biology, adaptogens, and regenerative nutrition. The company’s mission is to enhance the quality of life through innovation that works in harmony with the body’s natural processes.
For more information, visit: www.bioadaptives.com
Contact:
Emily Harrison
Investor Relations
BioAdaptives, Inc.
(702) 659-8829
info@bioadaptives.com
Wire Service Contact:
IBN
Austin, Texas
www.InvestorBrandNetwork.com
512.354.7000 Office
Editor@InvestorBrandNetwork.com
FAQ
When will BioAdaptives (BDPTD) launch NeuroRush™ nationally?
What ingredients are included in BioAdaptives' NeuroRush™ supplement?
How will BioAdaptives distribute NeuroRush™?
What formulations of NeuroRush™ will BDPTD offer?
What benefits did test market users report for BioAdaptives' NeuroRush™?
